|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
2P30CA060553-24
|
$6,420,169
|
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Cancer Immunotherapy Trials Network Central Operations and Statistical Center
|
5UM1CA154967-08
|
$4,864,165
|
|
CHEEVER, MARTIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Childrens Oncology Group Pediatric Early Phase Clinical Trial Network
|
1UM1CA228823-01
|
$4,739,780
|
|
WEIGEL, BRENDA
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cancer Center Support Grant
|
2P30CA016359-39
|
$4,530,485
|
|
FUCHS, CHARLES
|
YALE UNIVERSITY
|
|
Understanding Ethnic Differences in Cancer: The Multiethnic Cohort Study
|
5U01CA164973-07
|
$3,418,975
|
|
LE MARCHAND, LOIC
|
UNIVERSITY OF HAWAII AT MANOA
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
5U01CA164974-08
|
$3,131,894
|
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA051008-16S3
|
$2,960,949
|
$29,609
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
SPORE in Gastrointestinal Cancers
|
2P50CA062924-24A1
|
$2,500,000
|
|
KLEIN, ALISON
|
JOHNS HOPKINS UNIVERSITY
|
|
Yale SPORE in Skin Cancer
|
2P50CA121974-11A1
|
$2,500,000
|
|
BOSENBERG, MARCUS
|
YALE UNIVERSITY
|
|
Brain Tumor SPORE Grant
|
2P50CA097257-16
|
$2,498,496
|
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
SPORE in Ovarian Cancer
|
1P50CA228991-01
|
$2,492,537
|
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Myeloid Malignancies
|
5P50CA206963-02
|
$2,300,000
|
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
SPORE for Translational Approaches to Brain Cancer
|
1P50CA221747-01A1
|
$2,300,000
|
|
LESNIAK, MACIEJ
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Specialized Program Of Research Excellence (SPORE) in Leukemia.
|
2P50CA171963-06
|
$2,299,839
|
|
LINK, DANIEL
|
WASHINGTON UNIVERSITY
|
|
SPORE in Bladder Cancer
|
1P50CA221745-01A1
|
$2,299,837
|
|
BAJORIN, DEAN
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance
|
5P01CA217959-02
|
$2,171,238
|
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
The Pacific Northwest Prostate Cancer SPORE
|
2P50CA097186-16A1
|
$2,155,387
|
|
NELSON, PETER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
|
1P01CA217805-01A1
|
$2,105,511
|
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma
|
1P01CA229100-01
|
$2,087,361
|
|
RIMSZA, LISA
|
MAYO CLINIC ARIZONA
|
|
Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC)
|
5U01DK108328-04
|
$1,900,000
|
|
YUAN, YING
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Molecular Pathogenesis of the Hamartoma Syndromes
|
2P01CA120964-11A1
|
$1,897,687
|
|
KWIATKOWSKI, DAVID
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Oncohistones: Role of Histone H3 Mutations in the Oncogenesis of Pediatric Cancers
|
5P01CA196539-04
|
$1,855,117
|
|
ALLIS, CHARLES
|
ROCKEFELLER UNIVERSITY
|
|
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA217685-02
|
$1,813,624
|
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Studies of Medical Radiation and Other Therapeutic Agents
|
Z01 CP010131
|
$1,766,702
|
$5,241
|
Ron
|
DCEG (NCI)
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
5U54CA163068-07
|
$1,751,252
|
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
TCIA Sustainment and Scalability - Platforms for Quantitative Imaging Informatics in Precision Medicine
|
5U24CA215109-02
|
$1,667,436
|
|
PRIOR, FRED
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ
|
5R01CA218429-02
|
$1,347,851
|
|
ROHAN, THOMAS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
South Carolina Cancer Disparities Research Center (SC CADRE)
|
5U54CA210962-02
|
$1,265,640
|
|
FORD, MARVELLA
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
South Carolina Cancer Disparities Research Center (SC CaDRe)
|
5U54CA210963-02
|
$1,261,263
|
|
SALLEY, JUDITH
|
SOUTH CAROLINA STATE UNIVERSITY
|
|
Consortium on Methods Evaluating Tobacco (COMET): FilterVentilation and Product Standards
|
5P01CA217806-02
|
$1,197,947
|
|
HATSUKAMI, DOROTHY
|
UNIVERSITY OF MINNESOTA
|
|
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer
|
5R44CA221559-02
|
$1,079,344
|
|
KANNAN, KAMAL
|
METACLIPSE THERAPEUTICS CORPORATION
|
|
Human Papillomavirus and Polyomavirus Associated Malignancies.
|
5R35CA209979-02
|
$1,041,403
|
|
GALLOWAY, DENISE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes
|
5R35CA220500-02
|
$1,032,000
|
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Monitoring immune response to immunotherapies in cancer patients with VisAcT PET tracer
|
5R44CA221624-02
|
$1,020,835
|
|
LEVI, JELENA
|
CELLSIGHT TECHNOLOGIES, INC.
|
|
Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy
|
5R35CA220434-02
|
$1,010,214
|
|
WEISSMAN, IRVING
|
STANFORD UNIVERSITY
|
|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
Clinical Development of JS-K for the Treatment of Cancer
|
5R44CA221570-02
|
$999,423
|
|
NOWOSLAWSKI, JOSEPH
|
JSK THERAPEUTICS, INC.
|
|
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
|
5R44CA221513-02
|
$982,509
|
|
DEVENPORT, MARTIN
|
ONCOIMMUNE, INC.
|
|
Molecular and immunologic evolution of melanomas from pre-neoplastic lesions
|
5R35CA220481-02
|
$951,000
|
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
A single-cell device to capture and analyze rare T-cells from solid tumors.
|
5R44CA199055-03
|
$920,072
|
|
MCCONNELL, TIMOTHY
|
ISOPLEXIS, INC.
|
|
HIV and Hepatocellular Carcinoma in Uganda: The H2U Consortium
|
5U54CA190165-05
|
$864,483
|
|
KIRK, GREGORY
|
JOHNS HOPKINS UNIVERSITY
|
|
Personalized cancer models to discover and develop new therapeutic targets.
|
5U01CA217883-02
|
$847,023
|
|
KEMP, CHRISTOPHER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Germline and Tumor Genomic Analyses of Breast Cancer in Latinas
|
5R01CA184585-05
|
$789,245
|
|
NEUHAUSEN, SUSAN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Engineering personalized micro-tumor ecosystems
|
5U01CA214411-02
|
$754,767
|
|
SENGUPTA, SHILADITYA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent
|
5R44CA180745-03
|
$752,754
|
|
KAHL, STEPHEN
|
MANZANITA PHARMACEUTICALS, INC.
|
|
Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma
|
5R44CA210848-02
|
$750,000
|
|
STRAUBE, RICHARD
|
SOLIGENIX, INC.
|
Total relevant funding to Salivary Glands for this search: $180,361
|